Jami Sayed Abdulla1, Brotendu Shekhar Roy2, Zhou Zhanwen1, Jiandang Shi3, Changhao Liu1. 1. Department of Spinal Surgery, General Hospital of Ningxia Medical University, Ningxia Medical University, 804 Shengli Street, Xingqing District, Yinchuan, 750004, Ningxia, People's Republic of China. 2. First Affiliated Hospital of Nanchang University, No.17 Yong Wai Zheng Street Donghu District, Nanchang, 330006, Jiangxi, People's Republic of China. 3. Department of Spinal Surgery, General Hospital of Ningxia Medical University, Ningxia Medical University, 804 Shengli Street, Xingqing District, Yinchuan, 750004, Ningxia, People's Republic of China. shi_jiandang@outlook.com.
Abstract
PURPOSE: The goal of this study was to review relevant randomized controlled trials in order to determine the clinical efficacy of golimumab in the treatment of ankylosing spondylitis (AS). METHODS: Using appropriate keywords, we identified relevant studies using PubMed, Cochrane and Embase. Key pertinent sources in the literature were also reviewed, and all articles published through November 2019 were considered for inclusion. For each study, we assessed odds ratios, mean difference and 95% confidence interval to assess and synthesize outcomes. RESULTS: We included nine studies with 6363 patients. Compared with placebo, golimumab would significant decreased the value of BASFI, BASMI, BASDAI, total back pain, JSEQ; increased the value of SF-36 PCS and SF-36 MCS; increased the incidence of BASDAI50, ASAS20, ASAS40 and ASAS partial remission. Compared with golimumab 50 mg, golimumab 100 mg would significantly decreased the value of BASFI and total back pain; increased the value of SF-36 PCS and SF-36 MCS; but also increased the incidence of SAE. CONCLUSIONS: Golimumab had a definite effect in the treatment of AS. The higher dose would obtain better efficacy but lead to the incidence of SAE.
PURPOSE: The goal of this study was to review relevant randomized controlled trials in order to determine the clinical efficacy of golimumab in the treatment of ankylosing spondylitis (AS). METHODS: Using appropriate keywords, we identified relevant studies using PubMed, Cochrane and Embase. Key pertinent sources in the literature were also reviewed, and all articles published through November 2019 were considered for inclusion. For each study, we assessed odds ratios, mean difference and 95% confidence interval to assess and synthesize outcomes. RESULTS: We included nine studies with 6363 patients. Compared with placebo, golimumab would significant decreased the value of BASFI, BASMI, BASDAI, total back pain, JSEQ; increased the value of SF-36 PCS and SF-36 MCS; increased the incidence of BASDAI50, ASAS20, ASAS40 and ASAS partial remission. Compared with golimumab 50 mg, golimumab 100 mg would significantly decreased the value of BASFI and total back pain; increased the value of SF-36 PCS and SF-36 MCS; but also increased the incidence of SAE. CONCLUSIONS: Golimumab had a definite effect in the treatment of AS. The higher dose would obtain better efficacy but lead to the incidence of SAE.
Authors: Robert D Inman; John C Davis; Désirée van der Heijde; Laura Diekman; Joachim Sieper; Sung Il Kim; Michael Mack; John Han; Sudha Visvanathan; Zhenhua Xu; Benjamin Hsu; Anna Beutler; Jürgen Braun Journal: Arthritis Rheum Date: 2008-11
Authors: Désirée van der Heijde; Atul Deodhar; Jürgen Braun; Michael Mack; Benjamin Hsu; Timothy A Gathany; Robert D Inman; Chenglong Han Journal: J Rheumatol Date: 2014-04-15 Impact factor: 4.666
Authors: Atul Deodhar; John D Reveille; Diane D Harrison; Lilianne Kim; Kim Hung Lo; Jocelyn H Leu; Elizabeth C Hsia Journal: J Rheumatol Date: 2017-12-15 Impact factor: 4.666
Authors: Jürgen Braun; Atul Deodhar; Robert D Inman; Désirée van der Heijde; Michael Mack; Stephen Xu; Benjamin Hsu Journal: Ann Rheum Dis Date: 2011-10-19 Impact factor: 19.103
Authors: Atul Deodhar; Jürgen Braun; Robert D Inman; Désirée van der Heijde; Yiying Zhou; Stephen Xu; Chenglong Han; Benjamin Hsu Journal: Ann Rheum Dis Date: 2014-11-11 Impact factor: 19.103
Authors: Jonathan Kay; Roy Fleischmann; Edward Keystone; Elizabeth C Hsia; Benjamin Hsu; Michael Mack; Neil Goldstein; Jürgen Braun; Arthur Kavanaugh Journal: Ann Rheum Dis Date: 2013-12-16 Impact factor: 19.103